Thrombolysis in massive and submassive pulmonary embolism during pregnancy and the puerperium: a systematic review
- 28 April 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Thrombosis and Thrombolysis
- Vol. 50 (4), 929-941
- https://doi.org/10.1007/s11239-020-02122-7
Abstract
Thrombolysis in high-risk pulmonary embolism (PE) patients is recommended worldwide; however, the evidence for thrombolysis during pregnancy and the immediate puerperium remains unclear. We conducted a systematic review from 1950 to 2019 through PubMed, Ovid/Willey, and Cochrane Library to assess the safety and effectiveness of thrombolysis during pregnancy and the immediate puerperium. Additionally, we characterized the clinical presentation, risk stratification, and diagnostic approach. We have communicated our results according to the PRISMA statement. We collected 141 records and, after critical assessment, included 47 case reports of 54 patients, including 43 and 11 patients during pregnancy and puerperium, respectively. During pregnancy, alteplase was the most frequent systemic thrombolytic agent used (67%), but only nine patients received the approved FDA regimen. With catheter-directed thrombolysis, low-dose thrombolytics and fragmentation were the most common regimens. Major bleeding occurred in 18% of cases, but there was no intracranial bleeding. One maternal death occurred secondary to refractory cardiogenic shock. Fetal mortality was 20%. During the immediate puerperium, nine patients received “off-label” first-, second-, and third-generation thrombolytic regimens, and four cases underwent catheter-directed thrombolysis. We observed nine major bleeding events, seven of which were from the uterine location and none of which were intracranial. In conclusion, overall, these data do not suggest prohibitive risk associated with thrombolysis for PE in pregnancy. Management of massive and high-risk submassive PE in pregnancy should be individualized to each patient. In the data presented, no fatal bleeding or intracranial bleeding was observed. Finally, future efforts should systematically collect and report data on high-risk PE in pregnancy and peripartum patients to improve the evidence-base clinical practice.Keywords
This publication has 81 references indexed in Scilit:
- The use of thrombolytic therapy in pregnancyObstetric Medicine, 2013
- Thrombolysis for the management of massive pulmonary embolism in pregnancyInternational Journal of Obstetric Anesthesia, 2013
- Tromboembolismo pulmonar agudo na gravidez. A propósito de um caso clínicoRevista Portuguesa de Cardiologia, 2012
- Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- How to Interpret Elevated Cardiac Troponin LevelsCirculation, 2011
- Thrombolysis for massive pulmonary embolism in pregnancy: a case reportInternational Journal of Emergency Medicine, 2011
- Immediate postpartum cardiorespiratory collapse: a management quandaryBlood Coagulation & Fibrinolysis, 2010
- Catheter-directed thrombolysis for thromboembolic disease during pregnancy: a viable optionThe Journal of Maternal-Fetal Medicine, 1999
- Successful treatment of massive pulmonary embolism with recombinant tissue type plasminogen activator (rt-PA) in a pregnant woman with intact gravidity and preterm labourIntensive Care Medicine, 1990